MedTrace Logo

Investigation of MDR1 Gene Polymorphism and Losartan Plasma Concentration in Patients Undergoing Hypertensive Episodes While Under Losartan Treatment

NCT05349825 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2022-04-27

No results posted yet for this study

Summary

Losartan is an antihypertensive drug belonging to the ARB family. It is characterized as the substrate of the Multi Drug Resistance-1 (MDR1) drug-efflux protein (a pump that ensures the removal of drugs/foreign substances out of the cell) encoded by the ATP Binding Cassette Subfamily B Member 1 (ABCB1) gene. A recent line of evidence indicates that potential polymorphisms in this gene tend to alter the absorption, transport, bioavailability of losartan, and, indirectly, its effectiveness in hypertension control. As identified by new research, the C3435T, G2677T, and C1236T polymorphic alleles of the MDR1 gene might alter the bioavailability and thus the effectiveness of losartan

Conditions

Interventions

DIAGNOSTIC_TEST

Genetic analysis and Losartan plazma level measurement

20 ml of blood was collected from the enrolled patients. 10 ml of blood was stored in the tubes with ethylene diamine tetraacetic acid (EDTA) until Deoxyribonucleic acid (DNA) isolation was performed at -20 degrees and plasma level was identified. The remaining 10 ml was centrifuged at 3500 rpm for 10 min, and the plasma was separated. The resulting plasmas were stored in the eppendorf tubes at -20°C until the tandem mass spectrometry measurement. The blood samples in EDTA tubes were then transferred for DNA analysis. . To measure plasma losartan concentration, after the frozen plasma samples stored in the eppendorfs were thawed and brought to room temperature, plasma losartan and EXP3174 levels of the patients were calculated using tandem mass spectrometry

Sponsors & Collaborators

  • Gazi University

    collaborator OTHER

  • Pamukkale University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-23
Primary Completion
2019-01-15
Completion
2019-01-15

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05349825 on ClinicalTrials.gov